A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...

Amgen (AMGN) is drawing fresh attention after Phase 3 data for subcutaneous TEPEZZA in Thyroid Eye Disease and strong weight ...

Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants ...

The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts ...

Amgen followed up on Viridian Therapeutics' sizable crash Monday, delivering positive results for its next-generation Tepezza.

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...

The TEPEZZA OBI trial evaluated the safety and efficacy of SC teprotumumab in patients with active TED and proptosis of 3mm or greater from baseline.

Viridian Therapeutics (VRDN) remains a 'Sell' as both lead TED assets underperform versus Amgen’s Tepezza, with limited ...

Amgen Inc. (NASDAQ:AMGN) is one of the 7 Most Profitable Value Stocks to Buy Right Now. Amgen Inc. (NASDAQ:AMGN) is one of ...

Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease: Thousand Oaks, California Wednesday, April 8 ...